Literature DB >> 6605270

Cytolysis of autologous fresh osteosarcoma cells by human cytotoxic T lymphocytes propagated with T cell growth factor.

Y Ichino, T Ishikawa.   

Abstract

Cytotoxic T lymphocytes (CTL) against autologous fresh osteosarcoma cells were generated in mixed lymphocyte tumor culture (MLTC), and then were propagated and maintained for up to 19 days with culture medium containing T cell growth factor (TCGF). CTL generated with MLTC and propagated with TCGF (TCGF-CL) lysed fresh autologous osteosarcoma cells, but not autologous phytohemagglutinin-blastoid lymphocytes. More than 90% of the propagated lymphoblastoid cells were E-rosette forming cells. A subpopulation of TCGF-CL was Leu-2a positive and Leu-3a negative CTL. The cytotoxic activity to the autologous tumor detected by 51Cr release assay was not blocked by cold allogeneic tumor cells from 4 out of 5 patients tested. Human leukocyte antigen and chromosomes of TCGF-CL showed no abnormality.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6605270

Source DB:  PubMed          Journal:  Gan        ISSN: 0016-450X


  6 in total

1.  Killer cells induced by stimulation with allogeneic tumor cells and subsequent culture with recombinant interleukin-2.

Authors:  T Fukiage; H Murakami; M Eura; T Ikawa; T Ishikawa
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  Adoptive transfer of TILs plus anti-PD1 therapy: An alternative combination therapy for treating metastatic osteosarcoma.

Authors:  Chao Wang; Ming Li; Rong Wei; Junlong Wu
Journal:  J Bone Oncol       Date:  2020-10-16       Impact factor: 4.072

3.  Propagation of cytotoxic effectors from chronic myeloid leukemia patients and cloning of cytotoxic T cells.

Authors:  R Somasundaram; S H Advani; S G Gangal
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

4.  Suppressor cells in the effector phase of autologous cytotoxic reactions in cancer patients.

Authors:  M Eura; T Maehara; T Ikawa; T Ishikawa
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

5.  A quest for therapeutic antigens in bone and soft tissue sarcoma.

Authors:  Satoshi Kawaguchi; Takuro Wada; Tomohide Tsukahara; Kazunori Ida; Toshihiko Torigoe; Noriyuki Sato; Toshihiko Yamashita
Journal:  J Transl Med       Date:  2005-08-08       Impact factor: 5.531

6.  Retrospective Analysis of Adoptive TIL Therapy plus Anti-PD1 Therapy in Patients with Chemotherapy-Resistant Metastatic Osteosarcoma.

Authors:  Xiang Zhou; Junlong Wu; Chunguang Duan; Yingjie Liu
Journal:  J Immunol Res       Date:  2020-10-01       Impact factor: 4.818

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.